Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Vifor Pharma stock

VIFN.SW
CH0364749348
A2DRZ4

Price

166.15
Today +/-
+0
Today %
+0 %
P

Vifor Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vifor Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vifor Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vifor Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vifor Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vifor Pharma Stock Price History

DateVifor Pharma Price
12/22/2022166.15 undefined
12/21/2022165.35 undefined

Vifor Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vifor Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vifor Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vifor Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vifor Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vifor Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vifor Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vifor Pharma’s growth potential.

Vifor Pharma Revenue, EBIT and net profit per share

DateVifor Pharma RevenueVifor Pharma EBITVifor Pharma Net Income
2026e3 B undefined948.4 M undefined692.86 M undefined
2025e2.71 B undefined801.47 M undefined583.34 M undefined
2024e2.42 B undefined543.66 M undefined326.31 M undefined
2023e2.12 B undefined468.18 M undefined280.64 M undefined
2022e1.9 B undefined408 M undefined240.27 M undefined
20211.75 B undefined351.8 M undefined144.4 M undefined
20201.71 B undefined260.3 M undefined359.6 M undefined
20191.88 B undefined325 M undefined159.1 M undefined
20181.58 B undefined227.4 M undefined152.4 M undefined
20171.29 B undefined134.3 M undefined1.15 B undefined
20161.17 B undefined236.4 M undefined237.1 M undefined
20153.79 B undefined451.84 M undefined301.06 M undefined
20143.42 B undefined370.19 M undefined284.45 M undefined
20133.36 B undefined390.4 M undefined296.2 M undefined
20123.29 B undefined345.9 M undefined253.5 M undefined
20113.19 B undefined326.9 M undefined223.1 M undefined
20103.1 B undefined320.9 M undefined230.4 M undefined
20093.28 B undefined263.9 M undefined210.2 M undefined
20083.13 B undefined263.4 M undefined188.4 M undefined
20072.6 B undefined154.3 M undefined134.1 M undefined
20062.21 B undefined111.6 M undefined103.4 M undefined
20052.14 B undefined101.8 M undefined79.9 M undefined
20042.96 B undefined96.9 M undefined77.4 M undefined
20032.73 B undefined91.3 M undefined66.6 M undefined
20022.33 B undefined87.3 M undefined59 M undefined

Vifor Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
1.271.71.731.791.92.072.162.332.732.962.142.212.63.133.283.13.193.293.363.423.791.171.291.581.881.711.751.92.122.422.713
-34.312.063.176.438.564.507.7817.238.35-27.603.4117.2520.494.73-5.252.673.361.971.7010.98-69.2210.6322.7018.50-9.162.878.2711.6414.3411.8410.59
12.4113.7714.6514.4814.9716.2117.8719.8019.0519.1718.4019.1116.9125.3223.8717.4016.4117.0317.3017.5421.1661.7859.8859.0359.4058.8961.69-----
0.160.230.250.260.290.340.390.460.520.570.390.420.440.790.780.540.520.560.580.60.80.720.770.941.1211.0800000
18283133455360879196101111154263263320326345390370451236134227325260351408468543801948
1.421.651.791.842.362.562.783.743.333.254.725.015.938.418.0310.3110.2310.4711.6110.8311.9020.2210.3814.3317.3115.2520.0121.4822.0822.4029.5531.62
0.020.030.030.030.040.050.050.060.070.080.080.10.130.190.210.230.220.250.30.280.30.241.150.150.160.360.140.240.280.330.580.69
-19.0516.0017.2420.5917.0710.4211.3211.8616.672.6030.3830.1040.3011.709.52-3.0413.4517.00-4.055.99-21.26383.97-86.754.61125.79-59.8966.6716.6716.4378.8318.70
--------------------------------
--------------------------------
6565656565656565656565.165.16564.864.965.164.964.964.964.8864.9164.8764.9265.0265.0565.036500000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Vifor Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vifor Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
                                                     
161.1103.654.47851.670.190.2100109.385.439.1113.854.6117.679.3299.4345.3355.1215.9238.53422.44183426.6402.7545.2738.3994.5
84.4156.5168.1223.6257.6272.3268.3328.4373.2354.5382.6338366.4501.8505.7489.6501.8497.3510.3507.2544.12699.3350411.3414.2411.2374.2
24.113.913.8177.112.735.446.628.520.61118.823.62238.138.650.147.139127.3737.684.36211264.981.268.5
101.3155.6163.8159.7190.1168.1197.1218.3217.8197.1188200.7221.6231.1324.3334.1356.1365.6353.1375.82383.81432.5232281.7348.6339.8347
3.78.68.611.77.11011.113.115.918.41422.730.72729.7108.965.68553.3133.6669.622.941.134.238.594.4
0.370.440.410.490.510.530.60.710.740.680.630.690.70.90.981.171.261.331.21.31.421.391.091.251.411.611.88
218243.6252.2251.8269.8269.4282.2302.5321.4317.6283.2288.7358.4392.5455.9448.9447.5438.4441.4441.09450.2479.2241.5269.9346.9302.4186.8
0.70.30.30.40.512.111.514.518.720.549.653.964.768.5123.4119.3130.6105.2142.8146.57140.43130.8122.2212.3514.4740.9482.6
31.497.88.47.714.46.38.61510.76.511.6000000000000000
000000000.010.010.040.080.090.240.270.220.210.20.20.190.513.391.551.581.491.491.4
00000000000.030.060.140.491.061.031.041.051.071.071.0901.11.091.090.970.99
0000000000004.613.115.713.321.520.620.532.9926.2333.717.688.581.5104.9165.6
0.250.250.260.260.280.30.30.330.370.360.410.490.661.21.931.831.851.821.871.872.224.043.033.253.533.63.22
0.620.690.670.750.790.830.91.031.111.041.041.181.362.12.933.113.153.073.183.645.434.134.54.935.215.1
                                                     
65655242.332.532.532.52626260.70.70.70.70.70.70.70.70.70.650.650.60.70.70.70.70.7
74.674.674.674.674.674.674.674.674.674.700000000000000000
0.260.220.240.270.250.250.260.270.220.250.330.40.510.650.821.031.31.461.641.832.032.23.233.253.523.863.75
-0.4-0.4-1.2-1-0.40.91.1-5.3-7.9-11.52.40.4-5.6-49.9-51.9-92.1-94.9-95.1-112-93.92-124.05-75.5-155.7-182.2-188.2-278.8-251.7
0000000000-9.1-1.5-6.30.7-19.9-17.4-10.2-7.6-3.8-5.23-1.315.720.21.4-0.63.90.5
0.390.360.360.380.360.350.370.360.320.340.320.40.490.60.750.921.21.361.521.731.92.143.093.073.333.593.5
123.4165.2162.2145.4160.1162.2186.9213.5258.1260.2189.7252.9319.4421.4449374.7399.1337.7342.20364.5514.2174.2156.4107.9162.1163.1
14.522.323.699.671.272.662.969.168.869.7125.1102.692.8124.6148.50131.5165.7192.8135.42164.72234.5224240321.4249.1203.6
60.558.95754.454.379.934.850.550.623.284.378.546.5158.5102.3302.2155.5276.6123.7173.85136.8862.21839795.2109.9137.7
000000000000000000000000000
0.010.0100.010.10.120.130.060.0500.010.050.140.270.290.010.140.140.090.030.141.830.010.10.020.020.48
0.20.260.250.310.380.430.410.40.430.360.410.490.60.970.990.680.830.920.750.340.82.640.590.590.540.540.98
00.0200000.060.220.360.360.260.240.210.470.991.220.910.650.570.570.490.280.10.460.60.60.11
23.832.132.132.334.735.132.430.833.332.433.437.137.943.668.763.1687473.980.6286.42149.941.834.420.430.723.9
2.826.126.72315.741.751.751.4214.916.214.79.419.295111.5104.6129.4117.4124.86279.4467.362.638.338.324.115.2
0.030.080.060.060.050.080.150.310.410.40.310.30.260.531.151.391.080.850.760.770.860.490.20.540.660.650.15
0.230.330.310.370.440.510.560.70.840.760.720.780.861.52.152.081.911.771.511.111.663.130.791.131.21.191.13
0.620.690.670.750.790.870.931.071.161.11.041.181.352.12.933.113.133.042.843.565.273.884.24.534.784.63
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vifor Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vifor Pharma's financial health and stability.

Assets

Vifor Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vifor Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vifor Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vifor Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
2125293441485359667780103134189210232255274334311370227124244273237265
14161718191822252937283637206135120727675768685146164215228319
000000000000000000000000000
5-11-3362144-65-10855-4342-72-91-25-103-94-150-95-104-41-259-211-217-12-170-85
110-1-3-23084-2085211599448876911471106204124812827
000000000012912363233343429231923238757
00000000001516233240514035214541394478283955
42411156791159-1510610015120411540336533631029132935552225860193524423527
-19-15-24-20-43-44-35-48-59-50-62-65-114-76-65-64-60-51-71-69-164-248-88-276-136-384-218
0-0.07-0.03-0.02-0.09-0.11-0.06-0.1-0.2-0.05-0.09-0.12-0.19-0.73-0.38-0.08-0.07-0.05-0.11-0.16-0.16-1.542.07-0.38-0.130.05-0.05
0.02-0.06-0.010-0.05-0.06-0.03-0.05-0.140-0.03-0.06-0.08-0.65-0.31-0.01-0.010.01-0.04-0.090-1.292.15-0.100.440.17
000000000000000000000000000
-0-0.01-0.02-00-00.060.160.13-0.05-0.050.020.060.430.03-0.05-0.18-0.14-0.25-0.04-0.061.17-1.790.35-0.05-0.02-0.02
000000000000-8-26-9-37-8-13-5-10-83-16-9-24-2
-0.01-0.02-0.03-0.01-0.010.010.070.130.11-0.07-0.08-0.010.020.38-0.01-0.03-0.19-0.24-0.35-0.18-0.181.04-1.880.16-0.24-0.27-0.21
000002929000000007185000-2134-45-45-90-60
-9-11-12-12-14-16-18-25-21-23-25-28-30-42-45-49-52-92-92-129-102-116-129-129-129-129-129
35-57-4923-26182099-24-1877-5454-28225469-13222183-241244-24144185263
22.326-12.4363670.8-25.2-64.247.349.689139.20.7326.9299.9271.9250.3239.9257.4285.95357.3310.1-28.2-82.2388.739.2308.6
000000000000000000000000000

Vifor Pharma stock margins

The Vifor Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vifor Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vifor Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vifor Pharma's sales revenue. A higher gross margin percentage indicates that the Vifor Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vifor Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vifor Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vifor Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vifor Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vifor Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vifor Pharma Margin History

Vifor Pharma Gross marginVifor Pharma Profit marginVifor Pharma EBIT marginVifor Pharma Profit margin
2026e61.7 %31.63 %23.11 %
2025e61.7 %29.56 %21.51 %
2024e61.7 %22.43 %13.46 %
2023e61.7 %22.08 %13.24 %
2022e61.7 %21.48 %12.65 %
202161.7 %20.05 %8.23 %
202058.89 %15.26 %21.08 %
201959.43 %17.31 %8.48 %
201859.06 %14.35 %9.62 %
201759.91 %10.4 %88.81 %
201661.81 %20.26 %20.32 %
201521.16 %11.92 %7.94 %
201417.54 %10.84 %8.33 %
201317.31 %11.62 %8.82 %
201217.05 %10.5 %7.7 %
201116.41 %10.26 %7 %
201017.41 %10.34 %7.42 %
200923.9 %8.05 %6.42 %
200825.33 %8.42 %6.02 %
200716.91 %5.94 %5.16 %
200619.14 %5.04 %4.67 %
200518.43 %4.75 %3.73 %
200419.19 %3.28 %2.62 %
200319.08 %3.35 %2.44 %
200219.82 %3.75 %2.53 %

Vifor Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Vifor Pharma earnings per share therefore indicates how much revenue Vifor Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vifor Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vifor Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vifor Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vifor Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vifor Pharma Revenue, EBIT and net profit per share

DateVifor Pharma Sales per ShareVifor Pharma EBIT per shareVifor Pharma Earnings per Share
2026e46.21 undefined0 undefined10.68 undefined
2025e41.79 undefined0 undefined8.99 undefined
2024e37.35 undefined0 undefined5.03 undefined
2023e32.67 undefined0 undefined4.32 undefined
2022e29.26 undefined0 undefined3.7 undefined
202126.99 undefined5.41 undefined2.22 undefined
202026.23 undefined4 undefined5.53 undefined
201928.86 undefined5 undefined2.45 undefined
201824.37 undefined3.5 undefined2.34 undefined
201719.9 undefined2.07 undefined17.67 undefined
201617.99 undefined3.64 undefined3.66 undefined
201558.42 undefined6.96 undefined4.64 undefined
201452.65 undefined5.71 undefined4.38 undefined
201351.76 undefined6.02 undefined4.56 undefined
201250.76 undefined5.33 undefined3.91 undefined
201149.11 undefined5.04 undefined3.44 undefined
201047.69 undefined4.93 undefined3.54 undefined
200950.48 undefined4.07 undefined3.24 undefined
200848.28 undefined4.06 undefined2.91 undefined
200739.95 undefined2.37 undefined2.06 undefined
200634.02 undefined1.71 undefined1.59 undefined
200532.89 undefined1.56 undefined1.23 undefined
200445.5 undefined1.49 undefined1.19 undefined
200341.98 undefined1.4 undefined1.02 undefined
200235.82 undefined1.34 undefined0.91 undefined

Vifor Pharma business model

Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.com.

Vifor Pharma SWOT Analysis

Strengths

  • Strong brand recognition in the pharmaceutical industry.
  • Diversified product portfolio with a focus on innovative pharmaceuticals.
  • Well-established distribution network and partnerships.

Weaknesses

  • Limited global presence compared to competitors.
  • Dependence on a few key products for revenue generation.
  • Relatively small research and development budget.

Opportunities

  • Growing global demand for pharmaceutical products, especially in emerging markets.
  • Potential for strategic partnerships and collaborations to expand market reach.
  • Increasing focus on personalized medicine and targeted therapies.

Threats

  • Intense competition from both established pharmaceutical companies and generic drug manufacturers.
  • Stringent regulatory requirements and increasing pricing pressures.
  • Risk of patent expirations and generic competition.

Vifor Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vifor Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Vifor Pharma shares outstanding

The number of shares was Vifor Pharma in 2023 — This indicates how many shares 65.005 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vifor Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vifor Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vifor Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vifor Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vifor Pharma dividend history and estimates

In 2023, Vifor Pharma paid a dividend amounting to 2.82 CHF. Dividend means that Vifor Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Vifor Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Vifor Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Vifor Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Vifor Pharma Dividend History

DateVifor Pharma Dividend
2026e7.47 undefined
2025e6.28 undefined
2024e3.77 undefined
2023e2.82 undefined
2022e2.57 undefined
20212 undefined
20202 undefined
20192 undefined
20182 undefined
20172 undefined
20161.8 undefined
20151.5 undefined
20141.4 undefined
20131.1 undefined
20120.9 undefined
20110.8 undefined
20100.75 undefined
20090.7 undefined
20080.6 undefined
20070.5 undefined
20060.43 undefined
20050.39 undefined
20040.36 undefined
20030.33 undefined

Vifor Pharma dividend payout ratio

In 2023, Vifor Pharma had a payout ratio of 65.23%. The payout ratio indicates the percentage of the company's profits that Vifor Pharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Vifor Pharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Vifor Pharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Vifor Pharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Vifor Pharma Payout Ratio History

DateVifor Pharma Payout ratio
2026e69.98 %
2025e69.83 %
2024e74.89 %
2023e65.23 %
2022e69.36 %
202190.09 %
202036.23 %
201981.77 %
201885.32 %
201711.33 %
201649.32 %
201532.34 %
201431.93 %
201324.12 %
201223.08 %
201123.26 %
201021.19 %
200921.6 %
200820.62 %
200724.27 %
200627.04 %
200531.45 %
200430.25 %
200332.04 %
200269.36 %
Unfortunately, there are currently no price targets and forecasts available for Vifor Pharma.

Vifor Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20211.94 1.92  (-0.93 %)2021 Q2
12/31/20202.49 4.49  (80.04 %)2020 Q4
6/30/20202.54 1.04  (-59.05 %)2020 Q2
12/31/20191.98 0.34  (-82.82 %)2019 Q4
6/30/20192.29 2.11  (-7.86 %)2019 Q2
12/31/20181.15 0.52  (-54.68 %)2018 Q4
6/30/20181.32 1.82  (37.61 %)2018 Q2
12/31/20171.02 0.67  (-34.51 %)2017 Q4
12/31/20161.73 1.31  (-24.68 %)2016 Q4
6/30/20162.53 2.45  (-3.13 %)2016 Q2
1
2
3

Vifor Pharma shareholders

%
Name
Stocks
Change
Date
98.39379 % CSL Ltd63,849,04548,677,1838/9/2022
0.20828 % The Vanguard Group, Inc.135,157710/31/2022
0.20263 % Florida State Board of Administration131,48782,3739/30/2022
0.17333 % California Public Employees' Retirement System112,479-8,0136/30/2021
0.15210 % PGGM Vermogensbeheer B.V.98,69759,14112/31/2021
0.07185 % California State Teachers Retirement System46,626-20,8246/30/2022
0.05772 % Nordea Funds Oy37,454-68,72410/31/2022
0.05235 % Deka Investment GmbH33,970-3,0616/30/2022
0.05093 % State Street Global Advisors (UK) Ltd.33,051-7,2136/30/2022
0.03637 % Valiant Bank AG23,6003409/30/2021
1
2
3
4
5
...
10

Vifor Pharma Executives and Management Board

Mr. Abbas Hussain57
Vifor Pharma Chief Executive Officer
Compensation 2.1 M
Mr. Jacques Theurillat62
Vifor Pharma Independent Chairman of the Board of Directors
Compensation 1.2 M
Dr. Romeo Cerutti59
Vifor Pharma Independent Vice Chairman of the Board
Compensation 326,000
Dr. Sue Mahony56
Vifor Pharma Independent Directors
Compensation 260,000
Prof. Dr. Michel Burnier67
Vifor Pharma Independent Directors
Compensation 231,000
1
2
3

Vifor Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Travere Therapeutics Stock
Travere Therapeutics
SupplierCustomer0,520,08-0,34-0,350,350,24
Evotec Stock
Evotec
SupplierCustomer0,49-0,31-0,50-0,60-0,69-0,14
Roche Holding Stock
Roche Holding
SupplierCustomer0,37-0,320,370,050,320,48
Omnicom Stock
Omnicom
SupplierCustomer0,320,06-0,530,310,560,41
Otsuka Holdings Stock
Otsuka Holdings
SupplierCustomer0,320,430,720,42-0,66-0,47
Fresenius Stock
Fresenius
SupplierCustomer0,26-0,070,44-0,13-0,69-0,42
Fresenius Medical Care Stock
Fresenius Medical Care
SupplierCustomer0,25-0,29-0,150,32-0,39-0,34
Kissei Pharmaceutical Stock
Kissei Pharmaceutical
SupplierCustomer0,120,140,380,570,340,29
CARA Therapeutics Stock
CARA Therapeutics
SupplierCustomer0,06-0,19-0,70-0,45-0,74-0,48
ChemoCentryx Stock
ChemoCentryx
SupplierCustomer0,040,26-0,66-0,620,03-0,33
1
2

Most common questions regarding Vifor Pharma

What values and corporate philosophy does Vifor Pharma represent?

Vifor Pharma AG represents a set of core values and corporate philosophy that guides its operations. The company's values include a strong commitment to patients, healthcare providers, and employees. Vifor Pharma AG strives to make a positive impact on patients' lives through innovative healthcare solutions. The company's corporate philosophy centers around trust, integrity, and excellence. Vifor Pharma AG focuses on continuous improvement and delivering value to its stakeholders. With a patient-centric approach, Vifor Pharma AG aims to enhance patient outcomes and drive sustainable growth in the pharmaceutical industry.

In which countries and regions is Vifor Pharma primarily present?

Vifor Pharma AG is primarily present in various countries and regions worldwide. Its presence can be seen in Europe, North America, and certain parts of Asia. The company operates in diverse markets, including Switzerland, Germany, Austria, France, the United Kingdom, the United States, China, and Japan. With a global reach, Vifor Pharma AG has established itself as a leading pharmaceutical player in these regions, offering innovative healthcare solutions and improving patient outcomes.

What significant milestones has the company Vifor Pharma achieved?

Vifor Pharma AG, a renowned pharmaceutical company, has achieved several significant milestones throughout its existence. Notably, it successfully developed and launched a groundbreaking medication for the treatment of iron deficiency anemia (IDA) called Ferinject®. This innovative intravenous iron replacement therapy has transformed patient care worldwide. Vifor Pharma AG has also made strides in the field of nephrology, advancing the treatment of chronic kidney disease (CKD) and associated complications. With a strong focus on research and development, Vifor Pharma AG continues to seek out new therapeutic options and strategic partnerships to further enhance patient outcomes and improve global healthcare.

What is the history and background of the company Vifor Pharma?

Vifor Pharma AG, a leading global pharmaceutical company, has a rich history and background. Established in 1872 and headquartered in Switzerland, Vifor Pharma focuses on innovative treatments for patients suffering from iron deficiency, nephrology, and cardio-renal disorders. The company has played a pivotal role in healthcare advancements, leveraging its expertise to develop high-quality and effective pharmaceutical products. Vifor Pharma operates globally, collaborating with healthcare professionals to improve patients' well-being. Committed to research, development, and sustainable growth, Vifor Pharma aims to enhance the lives of individuals worldwide through its innovative solutions in the medical field.

Who are the main competitors of Vifor Pharma in the market?

The main competitors of Vifor Pharma AG in the market include companies like Novartis, Roche, Sanofi, and AstraZeneca. These companies operate in similar therapeutic areas and engage in the development and commercialization of pharmaceutical products. Vifor Pharma AG competes with these companies through its innovative and high-quality offerings, strategic partnerships, and strong market presence. By continuously adapting and expanding its product portfolio, Vifor Pharma AG aims to maintain its competitive position within the pharmaceutical industry.

In which industries is Vifor Pharma primarily active?

Vifor Pharma AG is primarily active in the pharmaceutical industry.

What is the business model of Vifor Pharma?

The business model of Vifor Pharma AG focuses on the development, production, and commercialization of pharmaceutical products. As a global healthcare company, Vifor Pharma AG specializes in the field of iron deficiency, nephrology, and cardio-renal therapies. They aim to improve the quality of life for patients suffering from various medical conditions, including chronic kidney disease, iron deficiency anemia, and renal diseases. Vifor Pharma AG collaborates with healthcare professionals and organizations worldwide to bring innovative and effective treatments to market. By leveraging their expertise and research capabilities, Vifor Pharma AG continues to drive advancements in the field of pharmaceuticals and improve patient outcomes.

What is the P/E ratio of Vifor Pharma 2024?

The Vifor Pharma P/E ratio is 33.1.

What is the P/S ratio of Vifor Pharma 2024?

The Vifor Pharma P/S ratio is 4.46.

What is the AlleAktien quality score of Vifor Pharma?

The AlleAktien quality score for Vifor Pharma is 4/10.

What is the revenue of Vifor Pharma 2024?

The expected Vifor Pharma revenue is 2.42 B CHF.

How high is the profit of Vifor Pharma 2024?

The expected Vifor Pharma profit is 326.31 M CHF.

What is the business model of Vifor Pharma

Vifor Pharma AG is a Swiss pharmaceutical company specializing in the research, development, and marketing of medicines for patients with kidney diseases, iron deficiency anemia, and other important therapeutic areas. The company operates various divisions worldwide and is a leading provider of products in the healthcare industry.

What is the Vifor Pharma dividend?

Vifor Pharma pays a dividend of 2 CHF distributed over 1 payouts per year.

How often does Vifor Pharma pay dividends?

Vifor Pharma pays out a dividend 1 times a year.

What is the Vifor Pharma ISIN?

The ISIN of Vifor Pharma is CH0364749348.

What is the Vifor Pharma WKN?

The WKN of Vifor Pharma is A2DRZ4.

What is the Vifor Pharma ticker?

The ticker of Vifor Pharma is VIFN.SW.

How much dividend does Vifor Pharma pay?

Over the past 12 months, Vifor Pharma paid a dividend of 2 CHF . This corresponds to a dividend yield of about 1.2 %. For the coming 12 months, Vifor Pharma is expected to pay a dividend of 6.28 CHF.

What is the dividend yield of Vifor Pharma?

The current dividend yield of Vifor Pharma is 1.2 %.

When does Vifor Pharma pay dividends?

Vifor Pharma pays a quarterly dividend. This is distributed in the months of June, June, June, May.

How secure is the dividend of Vifor Pharma?

Vifor Pharma paid dividends every year for the past 24 years.

What is the dividend of Vifor Pharma?

For the upcoming 12 months, dividends amounting to 6.28 CHF are expected. This corresponds to a dividend yield of 3.78 %.

In which sector is Vifor Pharma located?

Vifor Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vifor Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vifor Pharma from 5/3/2022 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 4/29/2022.

When did Vifor Pharma pay the last dividend?

The last dividend was paid out on 5/3/2022.

What was the dividend of Vifor Pharma in the year 2023?

In the year 2023, Vifor Pharma distributed 2 CHF as dividends.

In which currency does Vifor Pharma pay out the dividend?

The dividends of Vifor Pharma are distributed in CHF.

All fundamentals about Vifor Pharma

Our stock analysis for Vifor Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.